Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-04-06
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT01572480
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Boston Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT01570387
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma
- Conditions
- PleuralMalignantMesothelioma
- Interventions
- Biological: TroVax®Drug: PemetrexedDrug: CisplatinDietary Supplement: Vitamin B12Dietary Supplement: Folic AcidDrug: Dexamethasone
- First Posted Date
- 2012-04-03
- Last Posted Date
- 2013-03-12
- Lead Sponsor
- Wales Cancer Trials Unit
- Target Recruit Count
- 26
- Registration Number
- NCT01569919
- Locations
- 🇬🇧
Velindre Cancer Centre, Cardiff, South Wales, United Kingdom
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2012-04-03
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 100
- Registration Number
- NCT01569204
- Locations
- 🇩🇪
1st Dept. of Medicine, Cologne University Hospital, Cologne, Germany
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 929
- Registration Number
- NCT01568866
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇦🇺Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Refractory Multiple MyelomaRelapsed Multiple Myeloma
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 722
- Registration Number
- NCT01564537
- Locations
- 🇺🇸
University of Arkansas Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Pacific Cancer Medical Center Inc, Anaheim, California, United States
🇺🇸West Contra Costa Healthcare District, Berkeley, California, United States
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT01562405
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hosptial, Boston, Massachusetts, United States
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 74
- Registration Number
- NCT01559935
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-03-16
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT01556438
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 33
- Registration Number
- NCT01555281
- Locations
- 🇨🇭
Kantonsspital Olten, Olten, Switzerland
🇨🇭UniversitätsSpital Zürich, Zürich, Switzerland
🇮🇹Istituto Europeo di Oncologia IEO, Milano, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.